Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Authors: Nuciforo, Paolo, Townend, John, Piccart, Martine J., Fielding, Shona, Gkolfi, Panagiota, El-Abed, Sarra, de Azambuja, Evandro, Werutsky, Gustavo, Bliss, Judith, Moebus, Volker, Colleoni, Marco, Aspitia, Alvaro Moreno, Gomez, Henry, Gombos, Andrea, Coccia-Portugal, Maria A., Tseng, Ling-Ming, Kunz, Georg, Lerzo, Guillermo, Sohn, Joohyuk, Semiglazov, Vladimir, Saura, Cristina, Kroep, Judith, Ferro, Antonella, Cameron, David, Gelber, Richard, Huober, Jens, Di Cosimo, Serena

Source: European journal of cancer. 181:92-101

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100181179667.0x000001&indx=1&recIds=ETOCvdc_100181179667.0x000001

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Authors: Loibl, Sibylle, Loirat, Delphine, Tolaney, Sara M., Punie, Kevin, Oliveira, Mafalda, Rugo, Hope S., Bardia, Aditya, Hurvitz, Sara A., Brufsky, Adam M., Kalinsky, Kevin, Cortés, Javier, O'Shaughnessy, Joyce A., Dieras, Véronique, Carey, Lisa A., Gianni, Luca, Gharaibeh, Mahdi, Preger, Luciana, Phan, See, Chang, Lawrence, Shi, Ling, Piccart, Martine J.

Source: European journal of cancer. 178:23-33

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100177957950.0x000001&indx=1&recIds=ETOCvdc_100177957950.0x000001

Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.

Authors: Krop, Ian E., Mittempergher, Lorenza, Paulson, Joseph N., Andre, Fabrice, Bonnefoi, Herve, Loi, Sherene, Loibl, Sibylle, Gelber, Richard D., Caballero, Carmela, Bhaskaran, Rajith, Dreezen, Christa, Menicucci, Andrea R., Bernards, Rene, van 't Veer, Laura J., Piccart, Martine J.

Source: JCO Precision Oncology; 12/1/2024, Vol. 8, p1-15, 15p

Subject Terms: EPIDERMAL growth factor receptors, BREAST tumors, ADJUVANT chemotherapy, PROGRESSION-free survival, CRIME & the press

Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer: A plain language summary.

Authors: Loibl, Sibylle, Loirat, Delphine, Tolaney, Sara M., Punie, Kevin, Dieras, Véronique, Carey, Lisa A., Gianni, Luca, Shah, Anuj, Phan, See, Ling Shi, Spears, Patricia A., Piccart, Martine J.

Source: Future Oncology; 2024, Vol. 20 Issue 34, p2609-2616, 8p

Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers.

Authors: Hilbers, Florentine S., Poncet, Coralie, Tryfonidis, Konstantinos, Viale, Giuseppe, Delaloge, Suzette, Pierga, Jean-Yves, Brain, Etienne G. C., Rubio, Isabel T., Thompson, Alastair M., Rutgers, Emiel J. T., Piccart, Martine J., van 't Veer, Laura J., Cardoso, Fatima

Source: NPJ Breast Cancer; 11/2/2024, Vol. 10 Issue 1, p1-8, 8p

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

Authors: Retèl, Valesca P., Byng, Danalyn, Linn, Sabine C., Jóźwiak, Katarzyna, Koffijberg, Hendrik, Rutgers, Emiel J., Cardoso, Fatima, Piccart, Martine J., Poncet, Coralie, van't Veer, Laura J., van Harten, Wim H.

Source: In European Journal of Cancer September 2020 137:193-203

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

Authors: Lambertini, Matteo, Agbor-Tarh, Dominique, Metzger-Filho, Otto, Ponde, Noam F., Poggio, Francesca, Hilbers, Florentine S., Korde, Larissa A., Chumsri, Saranya, Werner, Olena, Del Mastro, Lucia, Caparica, Rafael, Moebus, Volker, Moreno-Aspitia, Alvaro, Piccart, Martine J., de Azambuja, Evandro

Source: In ESMO Open 2020 5(6)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer

Authors: Maurer, Christian, Tulpin, Lorraine, Moreau, Michel, Dumitrescu, Cristina, de Azambuja, Evandro, Paesmans, Marianne, Nogaret, Jean-Marie, Piccart, Martine J., Awada, Ahmad

Source: In ESMO Open 2018 3(6)

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)

Authors: Loibl, Sibylle, de la Pena, Lorena, Nekljudova, Valentina, Zardavas, Dimitrios, Michiels, Stefan, Denkert, Carsten, Rezai, Mahdi, Bermejo, Begoña, Untch, Michael, Lee, Soo Chin, Turri, Sabine, Urban, Patrick, Kümmel, Sherko, Steger, Guenther, Gombos, Andrea, Lux, Michael, Piccart, Martine J., Von Minckwitz, Gunter, Baselga, José, Loi, Sherene

Source: In European Journal of Cancer November 2017 85:133-145

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules

Authors: Dafni, Urania, Karlis, Dimitris, Pedeli, Xanthi, Bogaerts, Jan, Pentheroudakis, George, Tabernero, Josep, Zielinski, Christoph C., Piccart, Martine J., de Vries, Elisabeth G.E., Latino, Nicola Jane, Douillard, Jean-Yves, Cherny, Nathan I.

Source: In ESMO Open 2017 2(4)

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Authors: Loi, Sherene, Haibe-Kains, Benjamin, Majjaj, Samira, Lallemand, Francoise, Durbecq, Virginie, Larsimont, Denis, Gonzalez-Angulo, Ana M., Pusztai, Lajos, Symmans, W. Fraser, Bardelli, Alberto, Ellis, Paul, Tutt, Andrew N. J., Gillett, Cheryl E., Hennessy, Bryan T., Mills, Gordon B., Phillips, Wayne A., Piccart, Martine J., Speed, Terence P., McArthur, Grant A., Sotiriou, Christos, Brugge, Joan S.

Source: Proceedings of the National Academy of Sciences of the United States of America, 2010 Jun 01. 107(22), 10208-10213.

Access URL: https://www.jstor.org/stable/25681755

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

Authors: Leo, Angelo Di, Desmedt, Christine, Bartlett, John M S, Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I, Larsimont, Denis, Poole, Christopher, Isola, Jorma, Earl, Helena, Mouridsen, Henning, O'Malley, Frances P, Cardoso, Fatima, Tanner, Minna, Munro, Alison, Twelves, Chris J, Sotiriou, Christos, Shepherd, Lois, Cameron, David, Piccart, Martine J, Buyse, Marc

Source: In Lancet Oncology 2011 12(12):1134-1142

Pattern of care in locally advanced breast cancer: Focus on local therapy

Authors: Sinacki, Marcin, Badzio, Andrzej, Wełnicka-Jaśkiewicz, Marzena, Bogaerts, Jan, Piccart, Martine J., Therasse, Patrick, Smith, Ian E., Hatschek, Thomas, Jassem, Jacek

Source: In The Breast 2011 20(2):145-150

A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37

Authors: Wapnir, Irene L., Aebi, Stefan, Geyer, Charles E., Zahrieh, David, Gelber, Richard D., Anderson, Stewart J., Robidoux, André, Bernhard, Jürg, Maibach, Rudolf, Castiglione-Gertsch, Monica, Coates, Alan S., Piccart, Martine J., Clemons, Mark J., Costantino, Joseph P., Wolmark, Norman

Source: In Clinical Breast Cancer 2008 8(3):287-292

HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies

Authors: Whenham, Nicolas, D'Hondt, Véronique, Piccart, Martine J.

Source: In Clinical Breast Cancer 2008 8(1):38-49

ISY3-4 - Metastatic breast cancer: time for action using in depth tumor molecular characterization

Authors: Piccart, Martine J., Zardavas, Dimitrios, Fumagalli, Debora, Goulioti, Theodora, Straehle, Carolyn

Source: In Annals of Oncology November 2015 26 Supplement 7:vii11-vii11

The evolution of treatment strategies: Aiming at the target

Authors: Dinh, Phuong, Sotiriou, Christos, Piccart, Martine J.

Source: In The Breast 2007 16 Supplement 2:10-16

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

Authors: Giuliani, Rosa, Durbecq, Virginie, Di Leo, Angelo, Paesmans, Marianne, Larsimont, Denis, Leroy, Jean-Yves, Borms, Marleen, Vindevoghel, Anita, Jerusalem, Guy, D’Hondt, Veronique, Dirix, Luc, Canon, Jean-Luc, Richard, Vincent, Cocquyt, Veronique, Majois, Françoise, Reginster, Michel, Demol, Jan, Kains, Jean-Pierre, Delree, Paul, Keppens, Carine, Sotiriou, Christos, Piccart, Martine J., Cardoso, Fatima

Source: In European Journal of Cancer 2007 43(4):725-735

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

Authors: Rugo, Hope S., Tolaney, Sara M., Loirat, Delphine, Punie, Kevin, Bardia, Aditya, Hurvitz, Sara A., O'Shaughnessy, Joyce, Cortés, Javier, Diéras, Véronique, Carey, Lisa A., Gianni, Luca, Piccart, Martine J., Loibl, Sibylle, Goldenberg, David M., Hong, Quan, Olivo, Martin, Itri, Loretta M., Kalinsky, Kevin

Source: NPJ Breast Cancer; 8/29/2022, Vol. 8 Issue 1, p1-10, 10p

Bringing Molecular Prognosis and Prediction to the Clinic

Authors: Colozza, Mariantonietta, Cardoso, Fatima, Sotiriou, Christos, Larsimont, Denis, Piccart, Martine J.

Source: In Clinical Breast Cancer 2005 6(1):61-76